ASCEND is a randomised, double blind Phase II study of LSTA1 (formerly CEND-1) with standard of care chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma (PDAC). LSTA1 is a novel agent which aims to improve delivery of chemotherapy treatments through the dense stroma of PDAC.
To determine the effect of adding LSTA1 to standard of care chemotherapy with gemcitabine and nab‐paclitaxel on progression free survival (PFS)
Lisata Therapeutics (formerly CEND Therapeutics)
Adults with histologically proven metastatic pancreatic ductal adenocarcinoma suitable for first line gemcitabine and nab‐paclitaxel chemotherapy.